Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALENTINE: Patritumab Deruxtecan in HR+/HER2- Breast Cancer
NCT05569811Phase 2Active, not recruiting
- Sponsor
- SOLTI
- Start
- Nov 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of patritumab deruxtecan in breast cancer, sponsored by SOLTI. Started Nov 2022; status: active, not recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05569811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569811.